HK Stock Market Move | RemeGen (09995) rose nearly 8% again, and multiple original research results on vedolizumab were released at the 2026 EAU conference.

REMEGEN (09956) rose nearly 8%, reaching 6.08% as of the time of publication, to 96.8 Hong Kong dollars, with a turnover of 238 million Hong Kong dollars. On the news side, from March 13th to 16th, the 2026 European Association of Urology (EAU) Annual Meeting was held in London, UK. At this year's meeting, several cutting-edge research results from China focusing on the innovative application of HER2-targeted antibody-drug conjugate (ADC) Vendetiuximab in the treatment of urothelial carcinoma were released. These results covered the entire spectrum of the disease from early to late-stage, from bladder cancer to upper urothelial carcinoma, providing strong new evidence for the precise and organ-preserving treatment of urothelial carcinoma. It is worth noting that REMEGEN recently released its performance report, with operating income of 3.251 billion RMB, an 89.36% year-on-year increase; and a net profit attributable to shareholders of 709 million RMB, turning losses into profits year-on-year. The increase in operating income was mainly due to an increase in sales of Taituximab for injection and Vendetiuximab for injection, leading to an increase in sales revenue; furthermore, the company granted Vor Biopharma Inc. exclusive development and commercialization rights for Taituximab worldwide except for Greater China, resulting in a significant increase in technology licensing revenue.